RxDoctor Payments Data

Jasminepreet Chohan, MD

Adult Medicine · Wantagh, NYNPI 1467912394

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 18 manufacturers reported payments, led by AbbVie at 32.8% of the total.

$3,695in general payments, 2019–2025

Across 165 payments — averaging $22.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$561
  • Amgen$345
  • GSK$293
  • Lilly USA, LLC$242
  • AstraZeneca$216
  • plus $827 from 12 others

What the payments were for

  • Food & beverage$3,695100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,695 in reported general payments places this provider in the 80th percentile of 101 adult medicine providers in New York.

See all adult medicine providers in New York

Medicare billing

Part B allowed, 2024
$48,908
Medicare patients
218
Services billed
611

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban25$17,997
Levothyroxine Sodium78$1,020
Rosuvastatin Calcium87$923
Atorvastatin Calcium92$854
SynthroidLevothyroxine Sodium11$823
Albuterol Sulfate HfaAlbuterol Sulfate18$710
Metoprolol Succinate46$650
Nifedipine ErNifedipine17$575
Cefpodoxime Proxetil15$540
Fluticasone Propionate32$508
Losartan Potassium52$499
Simvastatin26$377
Famotidine37$374
Escitalopram Oxalate27$354
Methylprednisolone49$342

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$94$17,99725 claims
AbbVieSynthroid$1,212$82311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 101 adult medicine providers in New York.

Other adult medicine in Wantagh

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →